Summary by Moomoo AI
Thermo Fisher Scientific reported flat revenue of $10.60 billion in Q3 2024, with GAAP EPS at $4.25 and adjusted EPS at $5.28. The company's GAAP operating margin was 17.3%, while adjusted operating margin reached 22.3%. Sequential improvement was observed in growth metrics compared to Q2.The company continued to advance its growth strategy through product innovation, launching the Thermo Scientific Iliad scanning transmission electron microscope for advanced materials research, and new life sciences solutions including the Applied Biosystems MagMAX Sequential DNA/RNA kit and Invitrogen Vivofectamine Delivery Solutions. Strategic partnerships were expanded with the National Cancer Institute and facility expansions in Cincinnati, Ohio, and Bend, Oregon.Looking ahead, Thermo Fisher raised its full-year adjusted EPS guidance to $21.35-$22.07, while maintaining revenue guidance of $42.4-$43.3 billion. The company's strong commercial performance and operational execution through its PPI Business System position it well to deliver on 2024 objectives.
